Connect with us

News

What Can Facetite Do for Aging Skin?

Published

on

Saggy skin, fine lines, and a soft jawline. Those are the signs of facial aging, and they can sneak up fast. But what if there’s a way to refresh your look without surgery? FaceTite offers a less invasive path to firmer, younger-looking skin. Are you curious if this cosmetic procedure could be the right fit for you? Here’s how FaceTite works and why it might be the right fit for your skin.

What Is FaceTite?

FaceTite is a minimally invasive cosmetic procedure that helps tighten skin and reduce fat in targeted areas of the face and neck. It uses radiofrequency-assisted lipolysis (RFAL), a type of technology that sends controlled heat beneath the skin.

Unlike other invasive procedures, the FaceTite procedure doesn’t require large cuts or general anesthesia. A small probe is inserted under the skin through a tiny opening, and the device works from both inside and outside to reshape and firm the area.

Advanced FaceTite skin treatments are a popular choice for people who want noticeable improvements without going through a full facelift or long recovery time.

How FaceTite Helps With Aging Skin

As we get older, our skin loses firmness and starts to sag. FaceTite treatments help fight these changes by tightening skin, reducing fat, and improving facial shape without the need for surgery.

FaceTite uses advanced healthcare technology to gently reshape your skin. One of the main ways FaceTite works is by heating the deeper layers of the skin. This heat triggers collagen production, which helps the skin become firmer and smoother over time. It’s especially useful for areas like the jawline, neck, and lower cheeks, where loose skin, sagging, or a double chin can make the face look older.

FaceTite also targets small fat pockets that cause puffiness or drooping. By gently melting this fat, the treatment helps you look more refreshed and toned..

Together, these effects help improve skin tone and lift facial features. That’s why many people turn to FaceTite when they first notice signs of aging.

FaceTite vs. Traditional Facelift

FaceTite and traditional facelifts both aim to improve signs of aging, but they work in very different ways. Surgical facelift is a surgical procedure that removes excess skin and tightens facial muscles. It’s best for people with advanced sagging and deeper wrinkles, but it requires cuts, stitches, and weeks of recovery.

FaceTite, on the other hand, is a non-surgical option that uses heat to tighten the skin and reduce fat. There are no large incisions, and most people can return to normal activities within a few days. While results may not be as dramatic as a full facelift, they are more natural-looking and come with fewer risks.

FaceTite is ideal for those with mild to moderate skin looseness who want real improvement without the long healing time or cost of surgery. It fills the gap between skincare products and surgical facelifts.

What to Expect During and After the Procedure

FaceTite is usually done in a doctor’s office and takes about an hour, depending on the areas being treated. Before the procedure begins, a local anesthetic is used to numb the area, so you stay comfortable. A small probe is then inserted under the skin through a tiny opening, and radiofrequency energy is applied to melt fat cells and tighten the skin.

After the treatment, you may notice mild swelling, redness, or bruising. These side effects are normal and usually fade within a few days. Most people can return to their usual activities in about two to three days, though it’s best to avoid heavy exercise for a week.

Results are gradual and improve over time. Many people start seeing changes within a few weeks, with full results showing up after three to six months as new collagen forms and the skin becomes firmer.

Is FaceTite Right for You?

FaceTite is a great option for people who want tighter, smoother skin without going through surgery. It works best for those with mild to moderate sagging in areas like the jawline, cheeks, and neck. If you’re starting to notice loose skin or a less defined facial shape, FaceTite can help improve your look with little downtime.

It’s also a good choice for people who want subtle, natural results rather than a dramatic change. However, FaceTite may not be the best fit if you have very loose skin or deep wrinkles. In those cases, a traditional facelift might be more effective.

The best way to know if FaceTite is right for you is to speak with a qualified provider. They can look at your skin, talk about your goals, and help you decide if this treatment matches what you’re looking for.

A New Look Is Closer Than You Think

Aging skin doesn’t need a dramatic fix. Most of the time, it just requires the right solution. FaceTite offers a simple, science-backed way to restore firmness for those who want real results without surgery. If you’re ready to restore a firmer, more defined look, it’s time to talk to a trusted provider and see if FaceTite is the right move for you.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.